You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Repatha

Showing 1 - 25 of 83
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Heart Transplant Trial in Omaha (Evolocumab (Repatha))

Active, not recruiting
  • Heart Transplant
  • Evolocumab (Repatha)
  • Omaha, Nebraska
    University of Nebraska Medical Center
Dec 15, 2022

Ischemic Stroke Trial in Los Angeles (Repatha)

Terminated
  • Ischemic Stroke
  • Repatha
  • Los Angeles, California
    UCLA
Jan 24, 2022

Carotid Artery Stenosis Trial in London (Evolocumab Auto-Injector [Repatha], Placebo Auto-Injector)

Active, not recruiting
  • Carotid Artery Stenosis
  • Evolocumab Auto-Injector [Repatha]
  • Placebo Auto-Injector
  • London, United Kingdom
    Imperial College Healthcare NHS Trust
Oct 12, 2022

Malignant Glioma, Glioblastoma Trial in Durham (Evolocumab)

Recruiting
  • Malignant Glioma
  • Glioblastoma
  • Durham, North Carolina
    Duke University Medical Center
Oct 13, 2022

ST Elevation Myocardial Infarction Trial in Bucheon (Repatha®)

Recruiting
  • ST Elevation Myocardial Infarction
  • Bucheon, Korea, Republic of
    Sejong General Hospital
Oct 10, 2023

STEMI, Dyslipidemias Trial (Evolocumab)

Not yet recruiting
  • STEMI
  • Dyslipidemias
  • (no location specified)
Oct 12, 2022

Diabetes, Type 2, Dyslipidemia Associated With Type II Diabetes, Percutaneous Coronary Intervention Trial in Falls Church

Terminated
Has Results
  • Diabetes Mellitus, Type 2
  • +2 more
  • Falls Church, Virginia
    Inova Fairfax Hospital
Dec 22, 2022

Coronary Artery Disease, Atherosclerosis of Coronary Artery Trial in Nijmegen (Evolocumab 140 MG/ML [Repatha])

Recruiting
  • Coronary Artery Disease
  • Atherosclerosis of Coronary Artery
  • Evolocumab 140 MG/ML [Repatha]
  • Nijmegen, Gelderland, Netherlands
    Radboud University Medical Center
Jan 11, 2022

ASCVD, Atherosclerotic Cardiovascular Disease, Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Trial (Evolocumab,

Not yet recruiting
  • ASCVD
  • +3 more
  • (no location specified)
Aug 3, 2023

Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreas Cancer Trial in Quebec city (Cholesterol metabolism disruption)

Recruiting
  • Pancreatic Ductal Adenocarcinoma
  • +3 more
  • Cholesterol metabolism disruption
  • Quebec city, Quebec, Canada
    CHU de Québec-Université Laval
Oct 17, 2022

Hypercholesterolemia, Cardiovascular Diseases Trial in Cincinnati (lerodalcibep, evolocumab, alirocumab)

Active, not recruiting
  • Hypercholesterolemia
  • Cardiovascular Diseases
  • lerodalcibep
  • +2 more
  • Cincinnati, Ohio
  • +2 more
Jul 13, 2022

ST Elevation Myocardial Infarction (STEMI) Trial (Rosuvastatin 20 mg, Evolocumab 140 mg/1 ml Subcutaneous Solution [REPATHA])

Not yet recruiting
  • ST Elevation Myocardial Infarction (STEMI)
  • Rosuvastatin 20 mg
  • Evolocumab 140 mg/1 ml Subcutaneous Solution [REPATHA]
  • (no location specified)
Feb 1, 2023

Heart Failure With Reduced Ejection Fraction Trial in Badalona, Sevilla, Valencia (Evolocumab)

Completed
  • Heart Failure With Reduced Ejection Fraction
  • Badalona, Barcelona, Spain
  • +2 more
Aug 10, 2022

Hyperlipidemia, Mixed Dyslipidemia Trial in Denver (Evolocumab)

Completed
Has Results
  • Hyperlipidemia
  • Mixed Dyslipidemia
  • Evolocumab
  • Denver, Colorado
    Research Site
Nov 3, 2022

Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia Trial in Yongin (Evolocumab 140 MG/ML, Rosuvastatin 5mg, Ezetimibe 10mg)

Recruiting
  • Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia
  • Evolocumab 140 MG/ML
  • +2 more
  • Yongin, Gyeonggi-do, Korea, Republic of
    Yongcheol Kim
Jan 6, 2023

Type 1 Diabetes Trial in New York (Evolocumab Cartridge, Atorvastatin Calcium Tablets, Ezetimibe Tablets)

Recruiting
  • Type 1 Diabetes
  • Evolocumab Cartridge
  • +6 more
  • New York, New York
  • +2 more
Nov 29, 2022

Prospective German Very High Cardiovascular Risk Patients

Recruiting
  • Dyslipoproteinemias
  • PCSK9 Inhibitor [EPC]
  • Standard lipid lowering therapy
  • Dresden, Germany
    Medizinische Klinik und Poliklinik III
Mar 18, 2022

Acute Coronary Syndrome Trial in Baltimore (Evolocumab, Placebo)

Active, not recruiting
  • Acute Coronary Syndrome
  • Baltimore, Maryland
    Steven Paul Schulman
Jan 19, 2022

Stable Coronary Disease Trial (Evolocumab)

Not yet recruiting
  • Stable Coronary Disease
  • (no location specified)
Dec 16, 2021

Lung Cancer Metastatic Trial in Durham (Nivolumab, Ipilimumab, Evolocumab)

Recruiting
  • Lung Cancer Metastatic
  • Durham, North Carolina
    Duke Univ. Medical Center
May 16, 2022

Type 2 Diabetes Trial in New York (Statin, PCSK9 inhibitor, Ezetimibe 10mg)

Recruiting
  • Type 2 Diabetes
  • New York, New York
    NYU Langone Health
Jan 14, 2022

Atherosclerotic Cardiovascular Disease Trial in Jacksonville (Evolocumab, Placebo)

Completed
Has Results
  • Atherosclerotic Cardiovascular Disease
  • Jacksonville, Florida
    University of Florida
Feb 16, 2022

Homozygous Familial Hypercholesterolemia Trial in Worldwide (lerodalcibep, evolocumab)

Active, not recruiting
  • Homozygous Familial Hypercholesterolemia
  • Evanston, Illinois
  • +11 more
Jul 13, 2022

Atherosclerotic Cardiovascular Disease Trial in Grenoble (Evolocumab 140 MG/ML [Repatha])

Recruiting
  • Atherosclerotic Cardiovascular Disease
  • Evolocumab 140 MG/ML [Repatha]
  • Grenoble, France
    Grenoble University Hospital
May 18, 2022

Type 2 Diabetes Trial in Helsinki (Evolocumab)

Completed
Has Results
  • Type 2 Diabetes Mellitus
  • Helsinki, Finland
    Helsinki University Hospital, Biomedicum 2U
Oct 28, 2021